Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: A systematic review

Transplant International

Volumn 27, Issue 10, 2014, Pages 1039-1049

  Cholongitas, Evangelos ^a   Mamou, Chrysanthi ^a   Rodríguez Castro, Kryssia I ^b   Burra, Patrizia ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

cyclosporine; everolimus; hepatocellular carcinoma recurrence; immunosuppression; liver transplantation; sirolimus; tacrolimus

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPARATIVE STUDY; DATA SYNTHESIS; FOLLOW UP; GRAFT RECIPIENT; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MEDLINE; PRIORITY JOURNAL; QUALITY CONTROL; RECURRENCE RISK; SYSTEMATIC REVIEW; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DRUG DELIVERY SYSTEM; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; INCIDENCE; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

CALCINEURIN INHIBITORS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DRUG DELIVERY SYSTEMS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TREATMENT OUTCOME;

EID: 84925633628     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12372     Document Type: Article

References (68)

1. Calne RY,. Immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1154.
2. de Mare-Bredemeijer EL, Metselaar HJ,. Optimization of the use of Calcineurin inhibitors in liver transplantation. Best Pract Res Clin Gastroenterol 2012; 26: 85.
3. Ojo AO, Held PJ, Port FK, et al,. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
4. Vivarelli M, Cucchetti A, Piscaglia F, et al,. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11: 497.
5. Gonwa TA,. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transpl 2001; 7 (11 Suppl 1): S22.
6. Hojo M, Morimoto T, Maluccio M, et al,. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530.
7. Neuhaus P, Klupp J, Langrehr JM,. mTOR inhibitors: an overview. Liver Transpl 2001; 7: 473.
8. Chapman TM, Perry CM,. Everolimus. Drugs 2004; 64: 861.
9. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM,. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237.
10. Liang W, Wang D, Ling X, et al,. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012; 18: 62.
11. Menon KV, Hakeem AR, Heaton ND,. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37: 411.
12. Mazzaferro V, Bhoori S, Sposito C, et al,. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011; 17 (Suppl 2): S44.
13. Tsochatzis E, Garcovich M, Marelli L, et al,. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver Int 2013; 33: 944.
14. Lim KC, Chow PK, Allen JC, et al,. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg 2011; 254: 108.
15. Cholongitas E, Shusang V, Germani G, et al,. Long-term follow-up of immunosuppressive monotherapy in liver transplantation: tacrolimus and microemulsified cyclosporin. Clin Transplant 2011; 25: 614.
16. De Simone P, Nevens F, De CL, et al,. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12: 3008.
17. Miyagi S, Kawagishi N, Sekiguchi S, et al,. The relationship between recurrences and immunosuppression on living donor liver transplantation for hepatocellular carcinoma. Transplant Proc 2012; 44: 797.
18. Mangus RS, Fridell JA, Vianna RM, Kwo PY, Chen J, Tector AJ,. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up. Liver Transpl 2012; 18: 786.
19. Vivarelli M, Cucchetti A, La BG, et al,. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857.
20. Hu AB, Wu LW, Tai Q, Zhu XF, He XS,. Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center. J Dig Dis 2013; 14: 38.
21. Aktas S, Karakayali H, Moray G, Ozdemir H, Haberal M,. Effects of risk factors and Ki-67 on rates of recurrence on patients who have undergone liver transplant for hepatocellular carcinoma. Transplant Proc 2011; 43: 3807.
22. O'Grady JG, Hardy P, Burroughs AK, Elbourne D,. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 2007; 7: 137.
23. Boudjema K, Camus C, Saliba F, et al,. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 2011; 11: 965.
24. Trunecka P, Boillot O, Seehofer D, et al,. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant 2010; 10: 2313.
25. de Ortiz UJ, Valdivieso A, Matarranz A, et al,. Advagraf de novo in liver transplantation: a single-center experience. Transplant Proc 2011; 43: 724.
26. Masetti M, Montalti R, Rompianesi G, et al,. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010; 10: 2252.
27. Soliman T, Hetz H, Burghuber C, et al,. Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation. Transpl Int 2007; 20: 447.
28. Fischer L, Klempnauer J, Beckebaum S, et al,. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transplant 2012; 12: 1855.
29. Castroagudin JF, Molina-Perez E, Ferreiro-Iglesias R, et al,. Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed? Transplant Proc 2012; 44: 1565.
30. Zimmerman MA, Trotter JF, Wachs M, et al,. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14: 633.
31. Rodrbox drawings light down and leftguez-Peralvarez M, Pieri G, Naveas MC, et al,. Immunosuppression and hepatocellular carcinoma recurrence after LT. J Hepatol 2013; 59: 1193.
32. Houssel P, Latournerie M, Jezequel C, et al,. Everolimus in liver transplantation to prevent HCC recurrence in the presence of extended Milan criteria. J Hepatol 2013; 58: S72.
33. Silva M, Moya A, Berenguer M, et al,. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl 2008; 14: 1449.
34. Ghanekar A, Kashfi A, Cattral M, et al,. Routine induction therapy in living donor liver transplantation prevents rejection but may promote recurrence of hepatitis C. Transplant Proc 2012; 44: 1351.
35. Di Benedetto F, Tarantino G, De Ruvo N, et al,. University of Modena experience in HIV-positive patients undergoing liver transplantation. Transplant Proc 2011; 43: 1114.
36. Nocera A, Andorno E, Tagliamacco A, et al,. Sirolimus therapy in liver transplant patients: an initial experience at a single center. Transplant Proc 2008; 40: 1950.
37. Vivarelli M, Dazzi A, Zanello M, et al,. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010; 89: 227.
38. Chen YB, Sun YA, Gong JP,. Effects of rapamycin in liver transplantation. Hepatobiliary Pancreat Dis Int 2008; 7: 25.
39. Zieniewicz K, Patkowski W, Nyckowski P, et al,. Results of liver transplantation for hepatocellular cancer. Ann Transplant 2007; 12: 11.
40. Toso C, Meeberg GA, Bigam DL, et al,. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007; 83: 1162.
41. Cholongitas E, Theocharidou E, Antoniadis N, et al,. The conversion to everolimus-based immunosuppression in liver transplant recipients ameliorates renal function and prevents hepatocellular recurrence without any rejection episode. J Hepatol 2013; 58: S63.
42. Saliba F, Dharancy S, Lorho R, et al,. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl 2011; 17: 905.
43. Schleicher C, Palmes D, Utech M, et al,. Timing of conversion to mammalian target of rapamycin inhibitors is crucial in liver transplant recipients with impaired renal function at transplantation. Transplant Proc 2010; 42: 2572.
44. Varona MA, Del Pino JM, Barrera M, et al,. Hepatocellular carcinoma and liver transplantation: a 12-year experience. Transplant Proc 2009; 41: 1005.
45. Hoffmann K, Hinz U, Hillebrand N, et al,. Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis. Clin Transplant 2011; 25: E541.
46. Balci D, Dayangac M, Yaprak O, et al,. Living donor liver transplantation for hepatocellular carcinoma: a single center analysis of outcomes and impact of different selection criteria. Transpl Int 2011; 24: 1075.
47. De Carlis L, Di Sandro S, Giacomoni A, et al,. Beyond the Milan criteria: what risks for patients with hepatocellular carcinoma progression before liver transplantation? J Clin Gastroenterol 2012; 46: 78.
48. Yoshizumi T, Ikegami T, Yoshiya S, et al,. Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma. Hepatol Res 2013; 43: 709.
49. Chan KM, Yu MC, Chou HS, Wu TJ, Lee CF, Lee WC,. Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation. Ann Surg Oncol 2011; 18: 2638.
50. Vakili K, Pomposelli JJ, Cheah YL, et al,. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Liver Transpl 2009; 15: 1861.
51. Sharma P, Schaubel DE, Messersmith EE, Guidinger MK, Merion RM,. Factors that affect deceased donor liver transplantation rates in the United States in addition to the Model for End-stage Liver Disease score. Liver Transpl 2012; 18: 1456.
52. Felga G, Evangelista AS, Salvalaggio PR, et al,. Hepatocellular carcinoma recurrence among liver transplant recipients within the Milan criteria. Transplant Proc 2012; 44: 2459.
53. Doyle MB, Vachharajani N, Maynard E, et al,. Liver transplantation for hepatocellular carcinoma: long-term results suggest excellent outcomes. J Am Coll Surg 2012; 215: 19.
54. An HJ, Jang JW, Bae SH, et al,. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2012; 18: 1406.
55. Escartin A, Sapisochin G, Bilbao I, et al,. Recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc 2007; 39: 2308.
56. Kiyici M, Yilmaz M, Akyildiz M, et al,. Association between hepatitis B and hepatocellular carcinoma recurrence in patients undergoing liver transplantation. Transplant Proc 2008; 40: 1511.
57. Wu LW, Guo ZY, Tai Q, et al,. Steroid elimination within 24 hours after orthotopic liver transplantation: effectiveness and tolerability. Hepatobiliary Pancreat Dis Int 2012; 11: 137.
58. Vivarelli M, Dazzi A, Cucchetti A, et al,. Sirolimus in liver transplant recipients: a large single-center experience. Transplant Proc 2010; 42: 2579.
59. Zhou J, Wang Z, Wu ZQ, et al,. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008; 40: 3548.
60. Chinnakotla S, Davis GL, Vasani S, et al,. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15: 1834.
61. Tsoulfas G, Kawai T, Elias N, Ko SC, et al,. Long-term experience with liver transplantation for hepatocellular carcinoma. J Gastroenterol 2011; 46: 249.
62. Yu YD, Lee SG, Joh JW, et al,. Results of a phase 4 trial of Tacrobell(R) in liver transplantation patients: a multicenter study in South Korea. Hepatogastroenterology 2012; 59: 357.
63. Woo HY, Jang JW, Choi JY, et al,. Living donor liver transplantation in hepatocellular carcinoma beyond the Milan criteria. Liver Int 2008; 28: 1120.
64. Wang GY, Yang Y, Li H, et al,. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS ONE 2011; 6: e25295.
65. Bertuzzo VR, Cescon M, Ravaioli M, et al,. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation 2011; 91: 1279.
66. Zimmerman MA, Kelly MA, Campsen J, et al,. The influence of OKT3 therapy on hepatocellular carcinoma recurrence following liver transplantation. Clin Transplant 2010; 24: E103.
67. Motomura T, Shirabe K, Mano Y, et al,. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013; 58: 58.
68. Kawahara T, Asthana S, Kneteman NM,. m-TOR inhibitors: what role in liver transplantation? J Hepatol 2011; 55: 144.